Table 2 Demographics, referral indications and cardiovascular disease identified during cardio-oncology clinic
From: Lessons learnt in the first year of an Australian pediatric cardio oncology clinic
N= | Percent | |
|---|---|---|
Sex | ||
Male | 22 | 59.5% |
Female | 15 | 40.5% |
Age | 37 | |
0–5 | 3 | 8.1% |
5–10 | 10 | 27% |
10–15 | 13 | 35.1% |
15–18 | 11 | 29.7% |
Disease | 37 | |
Leukaemia Post HSCT | 9 | 24.3% |
Ph + ALL Post HSCT | 2 | 5.4% |
ALL | 6 | 16.2% |
AML | 4 | 10.8% |
Hodgkin’s Lymphoma | 3 | 8.1% |
Non-Malignant Disease Post HSCT | 2 | 5.4% |
Sarcoma | 4 | 10.8% |
Langerhans Cell Histiocytosis | 1 | 2.7% |
PVL | 1 | 2.7% |
Brain tumour | 2 | 5.4% |
Wilm’s Tumour | 1 | 2.7% |
APML | 2 | 5.4% |
Reason for Referral | ||
Family history of genetic cardiac disease | 1 | 2.7% |
Hypertension | 1 | 2.7% |
New Murmur | 1 | 2.7% |
CAD > 250 mg/m2 and TKI | 2 | 5.4% |
CAD > 250 mg/m2 and immunotherapy | 1 | 2.7% |
CAD > 250 mg/m2 (off treatment) | 5 | 13.5% |
AYA pregnant after cancer therapy | 1 | 2.7% |
Tyrosine Kinase Inhibitors | 1 | 2.7% |
BRAF inhibitor | 2 | 5.8% |
Pre-existing or elevated biomarkers | 1 | 2.7% |
Left ventricular dysfunction (on treatment) | 9 | 24.3% |
Left ventricular dysfunction (off treatment prior TKI) | 1 | 8.1% |
Left ventricular dysfunction (off treatment) | 2 | 5.8% |
Any dose anthracycline and radiotherapy >15Gy with mediastinum in field | 1 | 2.7% |
Risk of QTc prolongation | 1 | 2.7% |
Other cardiac indication | 2 | 5.4% |
Off treatment (other indication) | 3 | 8.1% |
Family HX Bicuspid Valve | 2 | 5.4% |
Cardiovascular disease identified in clinic | ||
Hypertension | 12 | 32.4% |
Myocardial Infarction | 0 | 0% |
QTc prolongation | 2 | 5.4% |
Atrial Fibrillation | 0 | 0% |
Accelerated atherosclerosis | 0 | 0% |
Conduction disorder | 0 | 0% |
Arterial thrombotic event | 0 | 0% |
Left ventricular dysfunction | 7 | 18.9% |
Aortic Regurgitation | 1 | 2.7% |
Metabolic Syndrome | 1 | 2.7% |
BVD Needing Cascade Testing | 2 | 5.4% |
Other | 2 | 5.4% |